StockDuty ← Dashboard Oct 26, 2026 05:17 AM ET
SignalFDA/Bio

Innovent reports cancer drug results in breast, lung, pancreatic tumors

Cancer drug results reported across breast, lung, and pancreatic tumors.

What happened: Innovent Biologics (IVBIY)(IVBXF) reported encouraging clinical trial results for two experimental cancer drugs, presented at the European conference. Key numbers: 95% tumor response rate in patients with advanced breast cancer. Why it matters: The results include evidence of activity against several difficult-to-treat tumors, including breast, lung, and pancreatic tumors.
Innovent Biologics (IVBIY)(IVBXF) reported encouraging clinical trial results for two experimental cancer drugs, presented at the European conference.
The results include evidence of activity against several difficult-to-treat tumors, including breast, lung, and pancreatic tumors.
Sources